Table of Contents
- Key safety points
- Overview
- Forms and Bioavailability
- Evidence for Health Benefits
- Recommended Dosing
- Safety and Side Effects
- Drug Interactions
- Dietary Sources
- References
Key safety points
- With antidepressants, SAMe was linked to serotonin syndrome-like symptoms in a trial [12] and to a toxic interaction with clomipramine in a case report [39]. Do not stop or swap an antidepressant for SAMe without your doctor's advice. Serotonin syndrome can be deadly: for tremor, a racing heart, a high temperature, agitation or severe confusion, call your local emergency number (111 in NZ, 000 in Australia, 911 in the US, 999 in the UK) or go to the emergency department [40].
- SAMe has set off mania or hypomania, including in people with bipolar disorder [2, 45], and one volunteer had a mixed manic state with suicidal thoughts [33]. If you have bipolar disorder, take it only if your psychiatrist agrees. For suicidal thoughts, call your local emergency number (111 in NZ, 000 in Australia, 911 in the US, 999 in the UK) or go to the emergency department.
- SAMe may decrease the effects of levodopa [53], and SAMe injected into rat brains caused Parkinson's-like movement problems [47]. If you have Parkinson's disease, ask your neurologist first.
- In theory SAMe could promote Pneumocystis infection, so if you are immunocompromised, such as with HIV, ask your doctor first [53].
- Stomach discomfort (19%) and diarrhoea (20%) were the most frequent side effects of SAMe in a 12-week trial [38]; in a small Parkinson's study, 2 of 13 people stopped because of increased anxiety [23].
1. Overview
S-adenosyl-L-methionine (SAMe) is present in all living cells [1]. Cells make it from methionine in a reaction run by the enzyme methionine adenosyltransferase (MAT) [4]. SAMe is the starting point for three pathways: methylation, aminopropylation and transsulfuration [1]. As a methyl donor it acts on almost 100 different substrates, including DNA, RNA, proteins and lipids [51].
The three pathways work as follows:
- Transmethylation: SAMe hands a methyl group to DNA, RNA, proteins, lipids and other molecules [51], including those involved in making brain chemical messengers [3].
- Transsulfuration: through this route SAMe takes part in making glutathione, the main antioxidant inside cells [1, 49].
- Aminopropylation (polyamine synthesis): SAMe is the precursor for this route, which makes polyamines [1].
Making SAMe depends on methionine and on folate and vitamin B12, which recycle homocysteine back to methionine [50, 51]. Betaine (TMG) and choline offer a second recycling route [31].
SAMe is abundant in the liver [29], and every form of chronic liver injury lowers its production there [4]. SAMe was first described in 1952 [1], and clinical studies have covered depression, dementia, vacuolar myelopathy (a spinal cord disorder), liver disease and osteoarthritis [1]. It has been a prescription drug in Europe for depression and arthritis since 1975 and a supplement in the US since 1999 [35]. An evidence report for the US Agency for Healthcare Research and Quality (AHRQ) reviewed its use in depression, osteoarthritis and liver disease [37], and a 2017 review found promising but limited evidence for depression [42].
2. Forms and Bioavailability
Chemical Forms and Stabilization
The two multicentre trials that compared SAMe with imipramine used SAMe 1,4-butanedisulfonate, by mouth in one and by injection in the other [7].
Oral Bioavailability
SAMe taken by mouth is absorbed. In 15 healthy volunteers whose dose was built up over 5 days to 1,600 mg a day, blood SAMe levels rose significantly [33], and animal studies showed absorption from the gut [41].
3. Evidence for Health Benefits
Depression
Depression is the most studied use of SAMe. The 2016 Cochrane review included eight trials in 934 adults, comparing SAMe with placebo, imipramine, desipramine or escitalopram [2]. Low quality evidence showed SAMe and imipramine improved symptoms by similar amounts (SMD -0.04, 95% CI -0.34 to 0.27; 619 participants; 4 studies), and one trial found little difference from escitalopram [2]. As the only treatment, SAMe did not clearly beat placebo (SMD -0.54, 95% CI -1.54 to 0.46; 142 participants; 2 studies; very low quality evidence) [2]. The authors could not draw firm conclusions and called for large, high-quality trials [2]. A 2020 review of eight trials with 1,011 people found SAMe better than placebo in three of five comparisons and no different from imipramine or escitalopram in four [34].
Do not stop or swap a prescribed antidepressant for SAMe without your doctor's advice.
Mechanism: SAMe is a methyl donor involved in making several brain chemical messengers, and it has been proposed to have antidepressant properties [3].
SAMe vs. other antidepressants: Older trials compared SAMe with the tricyclic imipramine, and a newer one with escitalopram:
- Delle Chiaie et al. (Am J Clin Nutr 2002) ran two double-blind multicentre studies in major depression. In the first, 143 patients took 1,600 mg of oral SAMe a day and 138 took 150 mg of imipramine a day for 6 weeks; in the second, SAMe was given by injection for 4 weeks. Neither study found a difference in any efficacy measure, and adverse events were significantly fewer with SAMe [7].
- Mischoulon et al. (J Clin Psychiatry 2014) compared SAMe 1,600 to 3,200 mg a day, escitalopram 10 to 20 mg a day and placebo for 12 weeks in 189 outpatients. All three groups improved by about 5 to 6 points, with no significant differences: response rates were 36% for SAMe, 34% for escitalopram and 30% for placebo [38].
Placebo-controlled trials and pooled analyses: Salmaggi et al. (Psychother Psychosom 1993) gave 80 depressed women aged 45 to 59, after menopause, SAMe 1,600 mg a day or placebo for 30 days; symptoms improved more with SAMe from day 10 [8]. Kagan et al. (Am J Psychiatry 1990) found oral SAMe effective with few side effects in 15 inpatients with major depression [9]. A 1994 meta-analysis by Bressa found a higher response rate than placebo, with a global effect size of 17% to 38% depending on how response was defined, and an effect comparable with tricyclic antidepressants [10].
SAMe as adjunctive therapy to SSRIs/SRIs: One trial found a benefit from adding SAMe to a serotonin reuptake inhibitor:
- Papakostas et al. (Am J Psychiatry 2010) gave 73 people with major depression who had not responded to a serotonin reuptake inhibitor (SRI) SAMe (target 800 mg twice a day) or placebo for 6 weeks, alongside their usual SRI. Response rates were 36.1% with SAMe and 17.6% with placebo, and remission rates 25.8% and 11.7%. The authors called the results preliminary [11].
Lower-dose trials (both negative): Two trials gave 800 mg a day of SAMe with folinic acid and vitamin B12, one as an add-on and one as monotherapy, and neither clearly beat placebo:
- Sarris et al. (Eur Neuropsychopharmacol 2018) added SAMe with folinic acid and vitamin B12, or placebo, to antidepressants for 8 weeks in 107 outpatients whose depression had not remitted. There was no significant difference between groups: response rates were 54.3% with the SAMe combination and 50.0% with placebo. SAMe was linked to one case of serotonin syndrome-like symptoms [12].
- Sarris et al. (Psychopharmacology (Berl) 2020) gave 49 people with mild to moderate major depression, not taking antidepressants, SAMe with folinic acid and vitamin B12, or placebo, for 8 weeks. The combination reduced scores by 3.76 points more than placebo, but the difference was not significant (p = 0.13); an exploratory analysis found a benefit in those with milder depression (p = 0.045) [13].
Dose-response relationship: The positive add-on trial used 800 mg twice a day [11]; the negative one used 800 mg a day with folinic acid and vitamin B12 [12]. A 2002 review noted that some people may need doses higher than 1,600 mg a day [3].
Speed of onset: Kagan et al. described a rapid onset of action [9], and a 2002 review suggested SAMe may act faster than conventional antidepressants [3].
Osteoarthritis
Evidence for osteoarthritis is mixed. The 2009 Cochrane review by Rutjes et al. pooled four placebo-controlled trials with 656 patients with knee or hip osteoarthritis. The pain difference was small (SMD -0.17, 95% CI -0.34 to 0.01), about 0.4 cm on a 10 cm scale, and the trials were mainly small and of questionable quality; the review was inconclusive and advised against routine use [20].
An earlier meta-analysis by Soeken et al. (J Fam Pract 2002) pooled 11 studies. SAMe reduced functional limitation more than placebo but not pain, based on only 2 studies, and seemed comparable with NSAIDs, with fewer adverse effects [21].
Mechanism: SAMe has anti-inflammatory and pain-relieving effects [14]; animal studies showed anti-inflammatory activity when it was taken by mouth [41].
SAMe vs. NSAIDs (active comparator trials): Several trials compared SAMe with nonsteroidal anti-inflammatory drugs (NSAIDs):
- Caruso and Pietrogrande (Am J Med 1987) enrolled 734 patients with hip, knee, spine or hand osteoarthritis. SAMe 1,200 mg a day relieved pain as well as naproxen 750 mg a day, both beat placebo (p less than 0.01), and SAMe was better tolerated than naproxen [17].
- Kim et al. (Clin Ther 2009) randomised 134 Korean patients with knee osteoarthritis to SAMe 1,200 mg a day or nabumetone 1,000 mg a day for 8 weeks. Pain fell in both groups, with no significant difference in pain relief or tolerability [14].
- Najm et al. (BMC Musculoskelet Disord 2004) compared SAMe 1,200 mg with celecoxib 200 mg in a 16-week crossover trial in 61 adults with knee osteoarthritis. Celecoxib reduced pain more in the first month, but by the second month the groups did not differ. The authors concluded SAMe has a slower onset of action but is as effective as celecoxib [15].
- Domljan et al. (Int J Clin Pharmacol Ther Toxicol 1989) gave 20 patients with knee osteoarthritis SAMe 1,200 mg a day in week 1 and then 800 mg a day, or naproxen, and found no significant difference after 6 weeks [18].
SAMe vs. placebo (mixed results): Single placebo-controlled trials have been less consistent:
- Bradley et al. (J Rheumatol 1994) gave 81 patients with knee osteoarthritis 5 days of SAMe by injection followed by tablets, or placebo. SAMe reduced pain more than placebo at the site where patients had milder osteoarthritis, but not at the site where it was more severe [19].
Limitations: The placebo-controlled evidence is small and of poor quality [20].
Onset of action: SAMe took longer than celecoxib to work [15]. In the placebo-controlled trial that used injections first, benefit appeared as early as 14 days [19].
Depression in Parkinson's Disease
SAMe has been tested for depression in people with Parkinson's disease.
- Di Rocco et al. (Mov Disord 2000) gave SAMe 800 to 3,600 mg a day for 10 weeks to 13 depressed patients with Parkinson's disease whose earlier antidepressants had not helped or were not tolerated. Of 11 who finished, 10 improved by at least 50% on the Hamilton Depression Scale. Two stopped because of increased anxiety [23].
This was a small, uncontrolled study [23]. Levodopa uses up SAMe, and in rats SAMe injected into the brain caused Parkinson's-like movement problems [47].
Fibromyalgia
One small trial has tested SAMe for fibromyalgia [25].
- Jacobsen et al. (Scand J Rheumatol 1991) gave 44 patients with primary fibromyalgia 800 mg of oral SAMe a day or placebo for six weeks. SAMe improved disease activity, recent pain, fatigue, morning stiffness and mood on one scale. Tender points, muscle strength and mood on the Beck Depression Inventory did not differ from placebo [25].
Liver Disease
Every form of chronic liver injury lowers SAMe production in the liver, and SAMe protected the liver in animal models [4].
Mechanism: SAMe helps make glutathione, the main antioxidant inside cells [49], and restores glutathione stores in the liver [44].
Alcoholic liver disease: Trials in alcohol-related liver disease have mostly found no clear benefit:
- Mato et al. (J Hepatol 1999) gave 123 patients with alcoholic cirrhosis SAMe 1,200 mg a day by mouth or placebo for 2 years. Death or liver transplant fell from 30% with placebo to 16% with SAMe, but the difference was not significant (p = 0.077). With the sickest (Child class C) patients excluded, the figures were 29% and 12% (p = 0.025) [26].
- A Cochrane review (Rambaldi and Gluud, Cochrane Database Syst Rev 2006) of nine trials with 434 patients found no significant effect on death from any cause (RR 0.62, 95% CI 0.30 to 1.26) and could find no evidence supporting or refuting SAMe [27]. It was withdrawn in 2015 because it had not been updated [48].
- Medici et al. (Alcohol Clin Exp Res 2011) gave 37 patients 1.2 g of SAMe a day or placebo for 24 weeks while they abstained from alcohol. SAMe was no more effective than placebo [49].
Intrahepatic cholestasis of pregnancy: Cholestasis of pregnancy has been linked to adverse outcomes for mother and baby [28]:
- An early Cochrane review found four SAMe-versus-placebo trials in 82 women; only one showed greater improvement in itching, bile salts and liver enzymes [28].
- The 2020 update found insufficient evidence that SAMe is effective in cholestasis of pregnancy [43].
Nonalcoholic fatty liver disease (NAFLD): Interest here comes from animal work:
- Noureddin et al. (Exp Biol Med (Maywood) 2015) reported that mice lacking enzymes of SAMe metabolism develop nonalcoholic steatohepatitis (NASH), the inflammatory form of fatty liver disease [29].
A 2015 meta-analysis of 12 trials with 705 patients with chronic liver disease found some improvement in bilirubin and AST but not ALT, and judged SAMe of limited clinical value in certain liver diseases [44].
ADHD in Adults
SAMe has been tried in adult attention deficit-hyperactivity disorder (ADHD):
- Shekim et al. (Psychopharmacol Bull 1990) reported that 6 of 8 men with ADHD improved in a 4-week open trial, with minimal, short-lived side effects [46].
It had no control group [46].
4. Recommended Dosing
General Dosing Guidelines
Trials have given SAMe by mouth at 800 to 1,600 mg a day for depression [7, 11, 12], and at 1,200 mg a day for osteoarthritis [14, 17] and alcoholic liver disease [26]. A 2002 review cited doses of 200 to 1,600 mg a day for depression [3].
Dosing by Condition
| Condition | Daily Dose | Duration | Evidence Level |
|---|---|---|---|
| Depression (monotherapy) | 1,600 mg | 30 days to 6 weeks | Comparable with imipramine in a multicentre trial [7]; better than placebo in one trial [8] |
| Depression (adjunctive to SSRI/SRI) | 1,600 mg (800 mg twice daily) | 6 weeks | One small positive trial [11]; 800 mg/day with folinic acid and B12 did not beat placebo [12] |
| Osteoarthritis | 1,200 mg | 8 to 16 weeks | Comparable with NSAIDs [14, 15, 17]; Cochrane review of placebo trials inconclusive [20] |
| Fibromyalgia | 800 mg | 6 weeks | One small trial [25] |
| Liver disease | 1,200 mg | 24 weeks to 2 years | No clear benefit: 2-year trial not significant overall [26]; none at 24 weeks [49] |
| Parkinson's disease depression | 800-3,600 mg/day | 10 weeks | One small uncontrolled study [23] |
Practical Dosing Advice
Starting dose: In one study the dose was built up over 5 days to 1,600 mg a day [33].
Time to benefit: In depressed women after menopause, SAMe beat placebo from day 10 [8]. In knee osteoarthritis, celecoxib worked faster in the first month and SAMe caught up by the second [15].
Relationship to TMG, Folate, and B12
After SAMe donates its methyl group, the homocysteine left over is recycled to methionine by one of two routes [31, 51]:
- Methylfolate + vitamin B12: the enzyme methionine synthase needs folate and vitamin B12 to convert homocysteine back to methionine [50, 51].
- Trimethylglycine (TMG/betaine): betaine and choline provide methyl groups by a separate route, and betaine supplements lower homocysteine after a methionine load [31].
Low folate, B12 or betaine can therefore limit SAMe production and raise homocysteine [31, 50].
From the MicroVitamin range
MicroVitamin includes the nutrients this section describes: 400 mcg DFE of methylated folate, 12 mcg of methylated B12 as methylcobalamin, and 500 mg of TMG (betaine). MicroVitamin. See MicroVitamin
5. Safety and Side Effects
Common Side Effects
In trials, side effects of SAMe were mostly mild [34]. The most commonly reported are:
- Gastrointestinal: In a 12-week trial, stomach discomfort (19%) and diarrhoea (20%) led the side effects of SAMe [38]. A small Parkinson's study recorded mild nausea in one person and mild diarrhoea in two [23].
- Anxiety or restlessness: Two of 13 people with Parkinson's disease stopped SAMe because of increased anxiety [23].
Serious Concerns
Bipolar disorder: SAMe can trigger mania. An open trial saw mania in two patients with bipolar disorder [45], one placebo-controlled trial saw it in a patient with no history of mania [9], and the Cochrane review recorded two reports of mania or hypomania among 441 people taking SAMe [2]. A healthy volunteer taking 1,600 mg a day developed a mixed manic state with suicidal thoughts within 2 weeks and recovered within 3 days of stopping [33]. People with known or suspected bipolar disorder should take SAMe only if their psychiatrist agrees.
Serotonergic reaction: In an 8-week trial of SAMe, given with folinic acid and vitamin B12, added to antidepressants, SAMe was linked to one case of serotonin syndrome-like symptoms [12]. A case report also described a toxic interaction between SAMe and the tricyclic antidepressant clomipramine [39]. Serotonin syndrome can be deadly; its features include tremor, overactive reflexes, a racing heart, a high temperature, agitation and delirium (severe confusion) [40]. If these appear, call your local emergency number (111 in NZ, 000 in Australia, 911 in the US, 999 in the UK) or go to the emergency department.
Potential formation of toxic metabolites: In laboratory work, excess SAMe disrupted biological rhythms and was broken down to adenine and methylthioadenosine, which block methylation. The authors said the findings question the safety of SAMe as a supplement [35].
Homocysteine Concerns
SAMe turns into homocysteine after donating its methyl group, and raised homocysteine is a possible heart risk factor [32]. In a 4-week trial in 52 healthy volunteers, 800 mg a day did not change homocysteine, though liver enzyme ALT rose slightly at week 2 [32]. In 15 volunteers taking 1,600 mg a day for 4 weeks, no one's homocysteine rose [33]. Neither study lasted longer than 4 weeks.
Who Should Avoid SAMe
- People with bipolar disorder (risk of mania) [33, 45]
- People taking antidepressants, unless their doctor agrees [12, 39, 53]
- Pregnant or breastfeeding women, unless their doctor agrees: its safety during pregnancy has not been established [53]
- People who are immunocompromised, such as with HIV, unless their doctor agrees: in theory SAMe could promote Pneumocystis infection [53]
- People with Parkinson's disease taking levodopa, without their neurologist's advice [47]
6. Drug Interactions
SAMe may interact with some medicines and supplements [53]. If you take prescription medicines, check with your doctor or pharmacist before starting.
Serotonergic Medications
| Drug Class | Examples | Interaction | Clinical Advice |
|---|---|---|---|
| SSRIs | Fluoxetine, sertraline, escitalopram, paroxetine | Added to SRIs at 1,600 mg a day, SAMe was well tolerated in one trial [11]; at 800 mg a day with folinic acid and B12 it was linked to one case of serotonin syndrome-like symptoms [12] | Use only with your doctor's agreement |
| Tricyclic antidepressants | Imipramine, amitriptyline, nortriptyline | Toxic interaction with clomipramine in a case report [39]. One trial added SAMe to imipramine and found a faster early response, though scores did not differ by day 14 [34] | Do not combine without your doctor's agreement |
Dopaminergic Medications
Levodopa (for Parkinson's disease): SAMe may decrease the effects of levodopa [53]. Levodopa reacts with SAMe and depletes it, and in rats excess SAMe in the brain caused Parkinson's-like movement problems, which levodopa blocked [47]. People taking levodopa should use SAMe only with their neurologist's advice.
Other Interactions
SAMe might interact with medicines and supplements that raise serotonin, such as antidepressants, L-tryptophan and St John's wort [53].
7. Dietary Sources
The body makes SAMe from methionine [4]. Its production depends on getting enough of several nutrients:
Methionine
Methionine is an essential amino acid [51] found in dietary protein.
Folate (as Methylfolate)
Folate is needed to convert homocysteine to methionine in the making of SAMe [50]. It is found in vegetables (especially dark green leafy vegetables), fruits, nuts, beans, peas, seafood, eggs, dairy, meat, poultry and grains, and spinach, liver, asparagus and brussels sprouts are among the richest sources [50].
The RDA for folate is 400 mcg DFE (dietary folate equivalents) for adults [50]. About 25% of Hispanics, 10% of Caucasians and Asians, and 1% of African Americans are homozygous for the 677C>T MTHFR variant, which leaves less active folate (5-MTHF) and reduces methylation potential [50].
Vitamin B12
Vitamin B12 is a cofactor for methionine synthase, which converts homocysteine to methionine [51]. It is found in foods of animal origin and in some fortified plant foods such as breakfast cereals and nutritional yeasts [51]. Recommended intakes for adults range from 2.4 to 2.8 mcg [51].
Vitamin B6
Vitamin B6 helps keep homocysteine at normal levels [52]. Rich sources include fish, beef liver and other organ meats, potatoes and other starchy vegetables, and non-citrus fruit [52].
Practical Implications
Supporting the body's own production of SAMe requires:
- Enough protein (for methionine)
- Enough folate, B12 and B6 (for recycling and clearing homocysteine)
Chronic liver disease lowers SAMe production in the liver [4].
8. References
[1] Bottiglieri T. "S-Adenosyl-L-methionine (SAMe): from the bench to the bedside--molecular basis of a pleiotrophic molecule." Am J Clin Nutr. 2002;76(5):1151S-1157S. PMID: 12418493. https://pubmed.ncbi.nlm.nih.gov/12418493/
[2] Galizia I, Oldani L, Macritchie K, et al. "S-adenosyl methionine (SAMe) for depression in adults." Cochrane Database Syst Rev. 2016;10(10):CD011286. PMID: 27727432. https://pubmed.ncbi.nlm.nih.gov/27727432/
[3] Mischoulon D, Fava M. "Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence." Am J Clin Nutr. 2002;76(5):1158S-1161S. PMID: 12420702. https://pubmed.ncbi.nlm.nih.gov/12420702/
[4] Mato JM, Lu SC. "Role of S-adenosyl-L-methionine in liver health and injury." Hepatology. 2007;45(5):1306-1312. PMID: 17464973. https://pubmed.ncbi.nlm.nih.gov/17464973/
[7] Delle Chiaie R, Pancheri P, Scapicchio P. "Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies." Am J Clin Nutr. 2002;76(5):1172S-1176S. PMID: 12418499. https://pubmed.ncbi.nlm.nih.gov/12418499/
[8] Salmaggi P, Bressa GM, Nicchia G, et al. "Double-blind, placebo-controlled study of S-adenosyl-L-methionine in depressed postmenopausal women." Psychother Psychosom. 1993;59(1):34-40. PMID: 8441793. https://pubmed.ncbi.nlm.nih.gov/8441793/
[9] Kagan BL, Sultzer DL, Rosenlicht N, Gerner RH. "Oral S-adenosylmethionine in depression: a randomized, double-blind, placebo-controlled trial." Am J Psychiatry. 1990;147(5):591-595. PMID: 2183633. https://pubmed.ncbi.nlm.nih.gov/2183633/
[10] Bressa GM. "S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies." Acta Neurol Scand Suppl. 1994;154:7-14. PMID: 7941964. https://pubmed.ncbi.nlm.nih.gov/7941964/
[11] Papakostas GI, Mischoulon D, Shyu I, Alpert JE, Fava M. "S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial." Am J Psychiatry. 2010;167(8):942-948. PMID: 20595412. https://pubmed.ncbi.nlm.nih.gov/20595412/
[12] Sarris J, Byrne GJ, Bousman C, et al. "Adjunctive S-adenosylmethionine (SAMe) in treating non-remittent major depressive disorder: An 8-week double-blind, randomized, controlled trial." Eur Neuropsychopharmacol. 2018;28(10):1126-1136. PMID: 30115553. https://pubmed.ncbi.nlm.nih.gov/30115553/
[13] Sarris J, Murphy J, Stough C, et al. "S-Adenosylmethionine (SAMe) monotherapy for depression: an 8-week double-blind, randomised, controlled trial." Psychopharmacology (Berl). 2020;237(1):209-218. PMID: 31712971. https://pubmed.ncbi.nlm.nih.gov/31712971/
[14] Kim J, Lee EY, Koh EM, et al. "Comparative clinical trial of S-adenosylmethionine versus nabumetone for the treatment of knee osteoarthritis: an 8-week, multicenter, randomized, double-blind, double-dummy, Phase IV study in Korean patients." Clin Ther. 2009;31(12):2860-2872. PMID: 20110025. https://pubmed.ncbi.nlm.nih.gov/20110025/
[15] Najm WI, Reinsch S, Hoehler F, Tobis JS, Harvey PW. "S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial." BMC Musculoskelet Disord. 2004;5:6. PMID: 15102339. https://pubmed.ncbi.nlm.nih.gov/15102339/
[17] Caruso I, Pietrogrande V. "Italian double-blind multicenter study comparing S-adenosylmethionine, naproxen, and placebo in the treatment of degenerative joint disease." Am J Med. 1987;83(5A):66-71. PMID: 3318442. https://pubmed.ncbi.nlm.nih.gov/3318442/
[18] Domljan Z, et al. "A double-blind trial of ademetionine vs naproxen in activated gonarthrosis." Int J Clin Pharmacol Ther Toxicol. 1989;27(7):329-333. PMID: 2674027. https://pubmed.ncbi.nlm.nih.gov/2674027/
[19] Bradley JD, Flusser D, Katz BP, et al. "A randomized, double blind, placebo controlled trial of intravenous loading with S-adenosylmethionine (SAM) followed by oral SAM therapy in patients with knee osteoarthritis." J Rheumatol. 1994;21(5):905-911. PMID: 8064733. https://pubmed.ncbi.nlm.nih.gov/8064733/
[20] Rutjes AWS, Nüesch E, Reichenbach S, Jüni P. "S-Adenosylmethionine for osteoarthritis of the knee or hip." Cochrane Database Syst Rev. 2009;(4):CD007321. PMID: 19821403. https://pubmed.ncbi.nlm.nih.gov/19821403/
[21] Soeken KL, Lee WL, Bausell RB, Agelli M, Berman BM. "Safety and efficacy of S-adenosylmethionine (SAMe) for osteoarthritis." J Fam Pract. 2002;51(5):425-430. PMID: 12019049. https://pubmed.ncbi.nlm.nih.gov/12019049/
[23] Di Rocco A, Rogers JD, Brown R, Werner P, Bhatt K. "S-adenosyl-methionine improves depression in patients with Parkinson's disease in an open-label clinical trial." Mov Disord. 2000;15(6):1225-1229. PMID: 11104210. https://pubmed.ncbi.nlm.nih.gov/11104210/
[25] Jacobsen S, Danneskiold-Samsoe B, Andersen RB. "Oral S-adenosylmethionine in primary fibromyalgia. Double-blind clinical evaluation." Scand J Rheumatol. 1991;20(4):294-302. PMID: 1925418. https://pubmed.ncbi.nlm.nih.gov/1925418/
[26] Mato JM, Cámara J, Fernández de Paz J, et al. "S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial." J Hepatol. 1999;30(6):1081-1089. PMID: 10406187. https://pubmed.ncbi.nlm.nih.gov/10406187/
[27] Rambaldi A, Gluud C. "S-adenosyl-L-methionine for alcoholic liver diseases." Cochrane Database Syst Rev. 2006;(2):CD002235. PMID: 16625556. https://pubmed.ncbi.nlm.nih.gov/16625556/
[28] Burrows RF, Clavisi O, Burrows E. "Interventions for treating cholestasis in pregnancy." Cochrane Database Syst Rev. 2001;(4):CD000493. PMID: 11687082. https://pubmed.ncbi.nlm.nih.gov/11687082/
[29] Noureddin M, Mato JM, Lu SC. "Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine." Exp Biol Med (Maywood). 2015;240(6):809-820. PMID: 25873078. https://pubmed.ncbi.nlm.nih.gov/25873078/
[31] Obeid R. "The metabolic burden of methyl donor deficiency with focus on the betaine homocysteine methyltransferase pathway." Nutrients. 2013;5(9):3481-3495. PMID: 24022817. https://pubmed.ncbi.nlm.nih.gov/24022817/
[32] Thompson MA, et al. "Dietary supplement S-adenosyl-L-methionine (AdoMet) effects on plasma homocysteine levels in healthy human subjects: a double-blind, placebo-controlled, randomized clinical trial." J Altern Complement Med. 2009;15(5):523-529. PMID: 19422296. https://pubmed.ncbi.nlm.nih.gov/19422296/
[33] Gören JL, Stoll AL, Damico KE, Sarmiento IA, Cohen BM. "Bioavailability and lack of toxicity of S-adenosyl-L-methionine (SAMe) in humans." Pharmacotherapy. 2004;24(11):1501-1507. PMID: 15537554. https://pubmed.ncbi.nlm.nih.gov/15537554/
[34] Cuomo A, et al. "S-Adenosylmethionine (SAMe) in major depressive disorder (MDD): a clinician-oriented systematic review." Ann Gen Psychiatry. 2020;19:50. PMID: 32939220. https://pubmed.ncbi.nlm.nih.gov/32939220/
[35] Fukumoto K, et al. "Excess S-adenosylmethionine inhibits methylation via catabolism to adenine." Commun Biol. 2022;5(1):313. PMID: 35383287. https://pubmed.ncbi.nlm.nih.gov/35383287/
[37] Hardy ML, et al. "S-adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease." Evid Rep Technol Assess (Summ). 2003;(64):1-3. PMID: 12899148. https://pubmed.ncbi.nlm.nih.gov/12899148/
[38] Mischoulon D, et al. "A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder." J Clin Psychiatry. 2014;75(4):370-376. PMID: 24500245. https://pubmed.ncbi.nlm.nih.gov/24500245/
[39] Iruela LM, et al. "Toxic interaction of S-adenosylmethionine and clomipramine." Am J Psychiatry. 1993;150(3):522. PMID: 8434674. https://pubmed.ncbi.nlm.nih.gov/8434674/
[40] Spadaro A, Scott KR, Koyfman A, Long B. "High risk and low prevalence diseases: Serotonin syndrome." Am J Emerg Med. 2022;61:90-97. PMID: 36057215. https://pubmed.ncbi.nlm.nih.gov/36057215/
[41] Stramentinoli G. "Pharmacologic aspects of S-adenosylmethionine. Pharmacokinetics and pharmacodynamics." Am J Med. 1987;83(5A):35-42. PMID: 3318439. https://pubmed.ncbi.nlm.nih.gov/3318439/
[42] Sharma A, Gerbarg P, Bottiglieri T, et al. "S-Adenosylmethionine (SAMe) for Neuropsychiatric Disorders: A Clinician-Oriented Review of Research." J Clin Psychiatry. 2017;78(6):e656-e667. PMID: 28682528. https://pubmed.ncbi.nlm.nih.gov/28682528/
[43] Walker KF, Chappell LC, Hague WM, Middleton P, Thornton JG. "Pharmacological interventions for treating intrahepatic cholestasis of pregnancy." Cochrane Database Syst Rev. 2020;7:CD000493. PMID: 32716060. https://pubmed.ncbi.nlm.nih.gov/32716060/
[44] Guo T, et al. "S-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis." PLoS One. 2015;10(3):e0122124. PMID: 25774783. https://pubmed.ncbi.nlm.nih.gov/25774783/
[45] Lipinski JF, Cohen BM, Frankenburg F, et al. "Open trial of S-adenosylmethionine for treatment of depression." Am J Psychiatry. 1984;141(3):448-450. PMID: 6367496. https://pubmed.ncbi.nlm.nih.gov/6367496/
[46] Shekim WO, Antun F, Hanna GL, McCracken JT, Hess EB. "S-adenosyl-L-methionine (SAM) in adults with ADHD, RS: preliminary results from an open trial." Psychopharmacol Bull. 1990;26(2):249-253. PMID: 2236465. https://pubmed.ncbi.nlm.nih.gov/2236465/
[47] Charlton CG, Crowell B Jr. "Parkinson's disease-like effects of S-adenosyl-L-methionine: effects of L-dopa." Pharmacol Biochem Behav. 1992;43(2):423-431. PMID: 1359575. https://pubmed.ncbi.nlm.nih.gov/1359575/
[48] Rambaldi A, Gluud C. "WITHDRAWN: S-adenosyl-L-methionine for alcoholic liver diseases." Cochrane Database Syst Rev. 2015;(11):CD002235. PMID: 26560497. https://pubmed.ncbi.nlm.nih.gov/26560497/
[49] Medici V, Virata MC, Peerson JM, et al. "S-adenosyl-L-methionine treatment for alcoholic liver disease: a double-blinded, randomized, placebo-controlled trial." Alcohol Clin Exp Res. 2011;35(11):1960-1965. PMID: 22044287. https://pubmed.ncbi.nlm.nih.gov/22044287/
[50] National Institutes of Health, Office of Dietary Supplements. "Folate: Fact Sheet for Health Professionals." https://ods.od.nih.gov/factsheets/Folate-HealthProfessional/
[51] National Institutes of Health, Office of Dietary Supplements. "Vitamin B12: Fact Sheet for Health Professionals." https://ods.od.nih.gov/factsheets/VitaminB12-HealthProfessional/
[52] National Institutes of Health, Office of Dietary Supplements. "Vitamin B6: Fact Sheet for Health Professionals." https://ods.od.nih.gov/factsheets/VitaminB6-HealthProfessional/
[53] National Center for Complementary and Integrative Health. "S-Adenosyl-L-Methionine (SAMe): In Depth." Last updated January 2017. https://www.nccih.nih.gov/health/sadenosyllmethionine-same-in-depth



